跳至主要内容
临床试验/NCT01484808
NCT01484808Unknown不适用

Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage

University Urological Associates Inc.1 个研究点 分布在 1 个国家目标入组 6,600 人开始时间: 2012年1月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
6,600
试验地点
1

研究概览

简要总结

This is a review of previously published data from a large prostate cancer prevention study known as REDUCE. It is the investigators intention to review whether prostate specific antigen (PSA) velocity (change over time) will predict the presence of prostate cancer and its grade and stage (severity).

详细描述

This is a review of previously published data from a large prostate cancer prevention study known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to review whether PSA velocity (change over time) will predict the presence of prostate cancer and its grade and stage (severity) by two year biopsy. The investigator will review and compare data to a previously published study of similar design with finasteride.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
50 Years 至 74 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 50-74 years old with elevated PSA (>=4) along with negative entry biopsy of the prostate who had a subsequent biopsy by 24 months.

排除标准

  • Any positive biopsy of the prostate indicative of cancer upon entry

研究者

发起方
University Urological Associates Inc.
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验